XXEC Inc. Acquires Shares of 29,832 Heartflow, Inc. $HTFL

XXEC Inc. purchased a new position in shares of Heartflow, Inc. (NASDAQ:HTFL) during the third quarter, HoldingsChannel reports. The fund purchased 29,832 shares of the company’s stock, valued at approximately $1,004,000. Heartflow comprises 0.9% of XXEC Inc.’s investment portfolio, making the stock its 20th biggest position.

A number of other institutional investors have also recently bought and sold shares of the business. Baillie Gifford & Co. bought a new position in shares of Heartflow during the third quarter worth approximately $101,182,000. TD Asset Management Inc acquired a new position in Heartflow in the 3rd quarter valued at $2,692,000. New York State Common Retirement Fund acquired a new stake in shares of Heartflow during the 3rd quarter worth $4,015,000. Artisan Partners Limited Partnership bought a new position in shares of Heartflow in the third quarter worth $16,817,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Heartflow in the third quarter worth $13,887,000.

Insiders Place Their Bets

In related news, major shareholder Bain Capital Life Sciences Inv sold 2,000,000 shares of Heartflow stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $28.05, for a total transaction of $56,100,000.00. Following the sale, the insider directly owned 10,448,158 shares of the company’s stock, valued at approximately $293,070,831.90. The trade was a 16.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Campbell Rogers sold 65,153 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $24.49, for a total transaction of $1,595,596.97. Following the transaction, the insider owned 76,034 shares of the company’s stock, valued at approximately $1,862,072.66. This represents a 46.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,117,674 shares of company stock worth $59,052,646 in the last ninety days.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on HTFL shares. Wells Fargo & Company started coverage on shares of Heartflow in a research report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective for the company. Weiss Ratings restated a “sell (d)” rating on shares of Heartflow in a research report on Monday, December 29th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $40.00 price target on shares of Heartflow in a research report on Monday, March 9th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.50.

Heartflow Stock Performance

Heartflow stock opened at $22.52 on Wednesday. Heartflow, Inc. has a 52 week low of $20.13 and a 52 week high of $41.22. The stock has a market capitalization of $1.92 billion and a P/E ratio of -12.44. The stock has a fifty day moving average of $27.30 and a 200-day moving average of $30.52.

Heartflow Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.